An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to document quality of life, patient satisfaction, effect on itching, and control of psoriasis vulgaris associated with use of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% for treatment of plaque psoriasis under real-life conditions.

Official Title
-----------------
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Conditions
-----------------
Psoriasis Vulgaris

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed and dated informed consent obtained prior to any study related activities Aged 18 years or above Either sex Any race or ethnicity Attending a hospital outpatient clinic or the private practice of a board-certified dermatologist, dermatology-certified nurse practitioner or physician assistant trained in dermatology Clinical diagnosis of psoriasis vulgaris involving scalp and/or body amenable to treatment with a maximum of 100 g of topical medication per week. Patients who receive a prescription of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% as per an investigator's clinical judgment and in accordance with the US label, and who have access to the medication Able to communicate with the investigator, read and understand English, and understand and comply with the requirements of the study Exclusion Criteria: Prior treatment with calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension, 0.005%/0.064%. Contraindications or any warnings/precautions according to the US label. Current participation in any other interventional clinical study. Females who are pregnant, breast-feeding, or females of child-bearing potential wishing to become pregnant during the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dermatology Life Quality Index (DLQI) | Mean change from baseline | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale for itching | Mean percent change from baseline | 2 and 8 weeks | 
| Patient Global Assessment (PGA) | Percent of subjects with controlled disease | 2 and 8 weeks | 
| Dermatology Life Quality Index (DLQI) | Mean change from baseline | 2 weeks | 
| Treatment Satisfaction Questionnaire for Medication (TSQM)-9 |  | 2 and 8 weeks | 
| Dermatology Life Quality Index (DLQI) | Percent of patients that have a 5 point or greater change in total score | 2 and 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plaque psoriasis, calcipotriene, betamethasone dipropionate, topical